{"name":"Austrian Breast & Colorectal Cancer Study Group","slug":"austrian-breast-colorectal-cancer-study-group","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":3,"colorKey":"oncology","drugs":[{"name":"Fluorouracil implant","genericName":"Fluorouracil implant","slug":"fluorouracil-implant","indication":"Colorectal cancer","status":"phase_3"},{"name":"Tamoxifen + Aminoglutethimide","genericName":"Tamoxifen + Aminoglutethimide","slug":"tamoxifen-aminoglutethimide","indication":"Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease","status":"phase_3"},{"name":"Tamoxifen alone","genericName":"Tamoxifen alone","slug":"tamoxifen-alone","indication":"Hormone receptor-positive breast cancer (adjuvant and metastatic)","status":"phase_3"}]},{"name":"Other","slug":"other","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"immunology","drugs":[{"name":"Fluourouracil","genericName":"Fluourouracil","slug":"fluourouracil","indication":"Other","status":"discontinued"}]}],"pipeline":[{"name":"Fluorouracil implant","genericName":"Fluorouracil implant","slug":"fluorouracil-implant","phase":"phase_3","mechanism":"Fluorouracil implant delivers the chemotherapy agent 5-fluorouracil directly to tumor tissue to inhibit thymidylate synthase and disrupt DNA synthesis in cancer cells.","indications":["Colorectal cancer","Breast cancer"],"catalyst":""},{"name":"Fluourouracil","genericName":"Fluourouracil","slug":"fluourouracil","phase":"discontinued","mechanism":"Small molecule","indications":[],"catalyst":""},{"name":"Tamoxifen + Aminoglutethimide","genericName":"Tamoxifen + Aminoglutethimide","slug":"tamoxifen-aminoglutethimide","phase":"phase_3","mechanism":"Tamoxifen acts as a selective estrogen receptor modulator (SERM) to inhibit estrogen's action in breast tissue, while aminoglutethimide inhibits the enzyme CYP11A1, which is involved in the synthesis of steroids, including estrogen.","indications":["Adjuvant treatment of breast cancer in postmenopausal women with estrogen receptor-positive disease"],"catalyst":""},{"name":"Tamoxifen alone","genericName":"Tamoxifen alone","slug":"tamoxifen-alone","phase":"phase_3","mechanism":"Tamoxifen is a selective estrogen receptor modulator (SERM) that blocks estrogen binding to its receptor on breast cancer cells, inhibiting their growth.","indications":["Hormone receptor-positive breast cancer (adjuvant and metastatic)","Breast cancer prevention in high-risk women"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQcUJCcXFjMDBidzVVbVp1S2VHWU5VcHlBQndtbVBQak9tR0xmNkhFZ2swWndFUU5wUHJBM2ZCbEt2S0U2UE9FaExXZzZwVzVfOFd3TE1tWlRxMmtxd3VSS0RDZ0NuMm1kVTJILUhoRzMyaUF2d3VQLUJYVGczaTRGZnJyUXFkUnZydlIw?oc=5","date":"2025-08-09","type":"trial","source":"The Lancet","summary":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised trials of aromatase inhibitors in 22 031 postmenopausal women already treated with a","headline":"Extending the duration of endocrine treatment for early breast cancer: patient-level meta-analysis of 12 randomised tria","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMif0FVX3lxTE9WWkVFOXJWYzdsbWhwbGdVbHpuekxpa2RTcDNaQmg3X1ZCcllqNE9nNF9qLXpKX0dEM25PcUdwVGJyaFF6QUpzZFJwMWczdk95NFN4eUppNlR5eWw2OVNPcnR0aS01QWtpN3ZBNVNvRFJaczVNdGJ4bXVRME5WOGs?oc=5","date":"2025-07-30","type":"trial","source":"Medical Device Network","summary":"Natera initiates trial of Signatera test for breast cancer - Medical Device Network","headline":"Natera initiates trial of Signatera test for breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBXeUpiMnpnaC0wRl92b21RMGttUzd0WFQtWU1WajZ0SF9LT05uVG0zY1RHQnFrVTF5U21jS0pKU3R1c1hZdGhIcUtxdnpSNFlUclJXQWJfOUpHakNNQUo4?oc=5","date":"2025-01-21","type":"trial","source":"Nature","summary":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial - Nature","headline":"Neoadjuvant nivolumab and chemotherapy in early estrogen receptor-positive breast cancer: a randomized phase 3 trial","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijgFBVV95cUxNRVNYRzRUVHRBWFBISWlwY1RHZTRCSWJObk1WUUx6bVJTVkJUaFRVMU1yWDQ2MFJqYUhqanZKQ1MxQzRGOU1LMmRNYjdrdUhGRVZ6VE5yaUhkWG5sRVpLcVlrbWlEZG1tRWpqQzloZERBV0UxOXdJeXFPdW9HaEc0bTlJR0FZanF0UlhzeWtn?oc=5","date":"2024-12-18","type":"trial","source":"MedCity News","summary":"Future Trends for Clinical Trials in 2025 and Beyond - MedCity News","headline":"Future Trends for Clinical Trials in 2025 and Beyond","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwJBVV95cUxNVWlaSTRHWEFPYlI1MzBiQXktRTd4aHFiczdZYmZuRExKU250VVdiajVvcnYwMHpaV2l3aUFfT0pGYXVGZ3FDc2FfbHI3cVUtaTA0X3hyV3BHbWxYdERiT1FNQ0RiOEVXYnZXUV90VDVLa3pHSlQ0cnl0V3Y0b21LUXE0TWp2ekJtcVR2Y05fc05LTFlqMlA5Vm0zYVlDT3l0RmRWWWFaR1lhSlktVElSUE8wbE5pS0t2VXMteGZHaS1Dbm1VYXEyVG1uck9mZzJnXzZiYkpmeEw5eXJTVnFudkdob3RsVTNBbE5UazF3U0MzY0oydnVzeUY0Um5iSFI1TklV?oc=5","date":"2024-11-27","type":"regulatory","source":"Novartis","summary":"Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast cancer at high risk of recurrence - Novartis","headline":"Novartis Kisqali® receives European Commission approval in a broad population of patients with HR+/HER2- early breast ca","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxPbHNZQmJKQnN5d3BWWUYwZ1l5NUhiSW5ULWJyVmhKZk5qOGNZV3pyNHJ2dFhMaW00TnE1MERXUG56Vy11LV9jcGplaTl1MlJpZUtSX0tJcFlZdjk1Q3BjRDdtdXE3cWxZb3FMSlRITDlJSGRHQW00NlFUQlBBeDhTOGhMa0pHWlRuT3BZVg?oc=5","date":"2023-06-27","type":"pipeline","source":"Frontiers","summary":"Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-Positive Early Breast Cancer in Premenopausal Women - Frontiers","headline":"Ovarian Function Suppression With Luteinizing Hormone-Releasing Hormone Agonists for the Treatment of Hormone Receptor-P","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTFBuVTZrZUdnVEx5Sm1FZDBLaUIwZ0I0Wi1XSEFkVEZKVWVyRjBSSktNWmVCWEszcmNpcW13R0FYRmFzRDU5dnVPZVhFUkVSZl9hckNYMExoUmpCZW9LOHcw?oc=5","date":"2023-05-23","type":"pipeline","source":"Nature","summary":"International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01) - Nature","headline":"International research to address the challenges of metastatic breast cancer: the AURORA Program (BIG 14-01)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixgFBVV95cUxObFNQaDYxaW1RaXkwSjJmZ1BrUnpOVG5kb1FnU2Zyb0ZQd2d6MGw5UkpQMEw4Tk5QZ1Q3OTF1SnpwazZFcU9uYV9hcEpOQjlobENwRlFUYlJSd3diSlFXUzhJX0ozUzZiaS1xM0NBdXNXRlpVUnBYR2tleUVDclllLTNKQVlIWE1IVGplcTRwZDZhc1RENXpFckRGMER2TUlsODc3UUE0SVZBRXlmNkIyNUg2dlRWOTdBOWk1MUpaclVhYUVSRGc?oc=5","date":"2022-06-27","type":"pipeline","source":"Cancer Therapy Advisor","summary":"Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer - Cancer Therapy Advisor","headline":"Denosumab Improves Long-Term Outcomes in AI-Treated Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiYEFVX3lxTE4yVFByMUo1M1YxVElRTTR2QXpSeXdaMFpCRGF4YlI1OW9YXzJsejVuUUNiVUd1Ym94cTN5bzdRbmJET0tZMEtvRWcxSFNUQTdUMFA2c2hscWpXVmt5Qzhqbw?oc=5","date":"2021-07-28","type":"pipeline","source":"NEJM","summary":"Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer - NEJM","headline":"Duration of Adjuvant Aromatase-Inhibitor Therapy in Postmenopausal Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxQeGVUMmV1dko1RzY0MHlIVjJGUl8xTklzVng5cjFKYXNZTmNwa2JyM3YtSnl2SmNDdk04dXhMNjdqYjhlLURxQldxLXhOcTNjOHAxbDdnalczeDNzR1RZcmsxajg2UllZRXdqRGVsVmtlYnZlYUJVTm0yUXdWNTJiNVJGbUxTSTkyZ0VMZDU2QW9IQk5aRzVGb3Atbkc?oc=5","date":"2019-04-30","type":"pipeline","source":"pharmaphorum","summary":"Genetic test can predict efficacy of chemotherapy in breast cancer - pharmaphorum","headline":"Genetic test can predict efficacy of chemotherapy in breast cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTE1YRlUzZzN2SkdJU3JOcjNpMDN0VWptUGFYb1B3M2ZZWEdPV0FiTVNqYmt5RUhDZURMdm1fYkRMUEpFa1p3MjlOa00ySHpoWlBXT3Y1QUVrQzlmVEVM?oc=5","date":"2019-03-22","type":"pipeline","source":"ASCO Publications","summary":"Endocrine Therapy in Premenopausal Hormone Receptor–Positive Breast Cancer - ASCO Publications","headline":"Endocrine Therapy in Premenopausal Hormone Receptor–Positive Breast Cancer","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiywFBVV95cUxOeEtJeTlNdFEwN1ZkRzd4RVp5enhYX3BMbjU3UkR5MTEteHhQMnV5RGJJajFyN2Z3cEN1MmRCRlBmSVVYQk5wbTVaNDlUYVdHc0VVNjEyNzhpdndDT1NySS1sQWNnQ2lmelcxVDRYMlVUcEh1eXB2OUpJUHdlbDhld1lfQlZ3eFM4ejctWHhtMk81WEdWN2VTX2thT1RGRHB4XzhxNW55NEhSNGNIdDJkTS04T3RHMkFjQ3drVXVVaXVaR2duVVh2c0pwYw?oc=5","date":"2015-06-05","type":"trial","source":"Fierce Pharma","summary":"Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors - Fierce Pharma","headline":"Amgen Presents Phase 3 Data At ASCO Showing Prolia® (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Pa","sentiment":"neutral"}],"patents":[],"drugCount":4,"phaseCounts":{"phase_3":3,"discontinued":1},"enrichmentLevel":2,"visitCount":3,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}